In this study, we attempt to gain insights into the molecular mechanism underlying MDM2-mediated TGF-β resistance. MDM2 renders cells refractory to TGF-β by overcoming a TGF-β-induced G1 cell cycle arrest.
Introduction
Transforming growth factor β (TGF-β) is a multifunctional extracellular cytokine that regulates important cellular processes such as cell proliferation and differentiation, development, wound healing and angiogenesis. The signaling pathway through which TGF-β regulates these cellular processes has been elucidated extensively (Siegel and Massague, 2003) . There are two cell surface receptors for TGF-β, type I and II, which contain serine/threonine protein kinase activities in their intracellular domains. TGF-β primarily binds to and activates the type II receptor. The activated type II receptor then recruits the type I receptor into the complex, transphosphorylates it and thereby stimulates its protein kinase activity. Once activated, the type I receptor phosphorylates Smad2 or Smad3, which are members of the Smad transcription factor family. Phosphorylated Smad2 or Smad3 binds to another Smad protein, Smad4. The resulting Smad heterodimer then translocates into the nucleus, where it regulates the transcription of TGF-β responsive genes in a cell type-specific manner.
TGF-β is a potent inhibitor of proliferation in most normal and early-stage tumor cells of epithelial, endothelial and hematopoietic origins. On the other hand, TGF-β can also facilitate the growth and invasiveness of tumor cells by promoting angiogenesis, suppressing the host immune system, enhancing the tumor cell migration and adhesion, and stimulating the expression of metastasis-promoting proteases. Thus, late-stage metastatic tumors often produce increased amounts of TGF-β and, at the same time, become refractory to TGF-β induced growth inhibition. The development of resistance to TGF-β-induced growth inhibition allows these tumors to escape the negative growth impact of TGF-β while benefiting from its tumor-promoting effects (Siegel and Massague, 2003) . Previous studies have shown that tumor cells can develop TGF-β resistance following inactivation of components of the TGF-β signaling pathway (Siegel and Massague, 2003) , overexpression of oncogenes such as c-myc (Feng et al., 2002) or cdc25A (Iavarone and Massague, 1997) , or deletion of the p15 INK4B locus (Hannon and Beach, 1994) . In addition, we have demonstrated that overexpression of an oncogene, MDM2, leads to TGF-β resistance in both mink lung 3 E06-09-0844 epithelial cells (Mv1Lu) and normal human mammary epithelial cells (Sun et al., 1998) . In human breast tumor cells, increased MDM2 expression correlates with loss of TGF-β sensitivity, suggesting that MDM2 overexpression is a potential mechanism for TGF-β resistance in human tumors.
MDM2 is a multifunctional oncoprotein, and its ability to inactivate the p53 tumor suppressor protein has been well characterized. MDM2 inhibits p53 functions through multiple mechanisms. The N-terminal p53-binding domain of MDM2 binds the transactivation domain of p53 and inhibits its transcriptional activity (Momand et al., 1992) . In addition, the MDM2/p53 complex shuttles from the nucleus to the cytoplasm (Tao and Levine, 1999a) , and the E3 ubiquitin ligase activity located in the C-terminal RING finger domain of MDM2 marks p53 and itself for degradation by ubiquitination (Honda et al., 1997; Fang et al., 2000) . The MDM2/p53 interaction is regulated by p19/p14 ARF , which sequesters MDM2 from p53 and blocks the ability of MDM2 to inhibit p53, leading to increased p53 activity (Honda and Yasuda, 1999; Tao and Levine, 1999b ).
p53-independent functions of MDM2 have also been described. MDM2 binds to and ubiquitinates the Retinoblastoma protein (Rb) (Xiao et al., 1995; Uchida et al., 2005) . This results in Rb degradation and release of the E2F1 transcription factor and cell cycle progression. MDM2 has also been reported to bind E2F1 directly and enhance E2F1 expression (Martin et al., 1995) . The p53 independent functions of MDM2 are supported by transgenic mouse models, in which overexpression of MDM2 in a p53 null background leads to multiple rounds of S-phase without cell division in mammary epithelial cells (Lundgren et al., 1997) and hyperproliferation of the skin (Alkhalaf et al., 1999) . It has also been described that overexpression of MDM2 in mice leads to spontaneous tumor formation in the absence of p53 (Carstens et al., 2004) .
Moreover, splice variants of the human counterpart of MDM2, HDM2, which contain partial or complete deletions of the p53-binding domain and do not bind p53 in vitro, retain significant tumorigenic activity in NIH3T3 cells (Sigalas et al., 1996; Harris, 2005) .
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The RING finger domain of MDM2 has received special attention because of its multiple functions. It contains an E3 ubiquitin protein ligase activity that is indispensable for the ubiqutination and degradation of p53. In particular, the zinc coordination residues C436, H455, C459 and C473 dictate the formation of the RING fingers and are essential for the E3 activity (Honda et al., 1997; Fang et al., 2000) . Interestingly, the ubiqutination and degradation of p53 requires not only the RING finger, but also a central acidic domain of MDM2 (Argentini et al., 2001; Kawai et al., 2003) . It is unclear whether the acidic domain is also required for the ubiquitination of other MDM2 substrates. The RING finger has also been described to interact with different proteins, such as MDMX and the transcription factor TAFII250 (Leveillard and Wasylyk, 1997; Tanimura et al., 1999) , and a specific 77-nucleotide RNA sequence that may be involved in gene translation (Elenbaas et al., 1996) . Furthermore, the RING finger can bind to nucleotides, which facilitates the nucleolar localization of MDM2 (Poyurovsky et al., 2003) . In an attempt to gain insights into the mechanism by which MDM2 leads to resistance to TGF-β induced growth arrest, we performed a structure-functional analysis of MDM2 in the current report. We have confirmed the ability of MDM2 to directly confer TGF-β resistance, and further showed that the resistance is due to bypass of the TGF-β induced G1 cell cycle arrest. Moreover, we have defined the structural requirements for MDM2-conferred TGF-β resistance. The results have indicated the essential roles of the C-terminal half of the p53-binding domain, the nuclear localization motif of MDM2 and the zinc coordination residues in the RING finger domain in TGF-β resistance in epithelial cells of both mink and human origins.
Experimental Procedures

Antibodies and Western Blotting analysis
Cell lysates were collected, separated by SDS-PAGE, and analyzed by Western Blotting as described previously (Wang et al., 2002) . To detect MDM2, an anti-MDM2 monoclonal antibody (2A10, a kind gift of Dr. Arnold Levine) (Xiao et al., 1995) was used in a dilution of 1:100. The HA-tagged MDM2 was detected with an anti-HA antibody (HA11, Covance). Detection of mink p53 was performed with an anti-p53 5 E06-09-0844 antibody CM5 (Novo Castra). Actin was detected using an anti-actin antibody (Sigma). MDMX-FLAG was detected using the anti-FLAG M5 antibody (Sigma). P53 and FLAG-MDMX were immunoprecipitated by an anti-p53 antibody (FL393, Santa Cruz) and an anti-FLAG M2 antibody (Sigma), respectively. A goatanti-mouse or a goat-anti-rabbit antibody (Jackson Immunoresearch) was used as secondary antibodies.
Cell culture
Mink lung epithelial cells (Mv1Lu), HEK293T and the amphotropic packaging cell line LinXA were grown in Dulbecco's modified essential medium containing L-glutamine, Penicillin/Streptomycin, sodium-pyruvate and 10% fetal calf serum (Gemini) at 37˚C in a humidified atmosphere containing 5% CO2. Human mammary epithelial cells (HMECs) were purchased from Cambrex and cultivated according to the manufacturer's instructions.
Retroviral vectors and retrovirus-mediated gene transduction
mdm2 was cloned as described previously (Sun et al., 1998) . For the deletions of the N-terminal and Cterminal regions of MDM2, cDNA encoding the corresponding mutants were amplified by PCR with the appropriate primers (sequence available upon request) and subcloned into the pWZL-hygro retroviral vector.
Point mutations of the RING finger domain of MDM2 were generated using the Quickchange mutagenesis kit (Stratagene). For the internal deletions of MDM2, the 5` region and the 3` region of each deletion were amplified separately by PCR and subcloned into pWZL-hygro containing an N-terminal epitope tag from the Haemaglutinin (HA) protein (sequence available upon request) via triple ligation. The deleted residues were replaced by 3 Ala encoded by 9 nucleotides that contained a NotI restriction site. All deletions were verified by sequencing analysis. An mdmx cDNA was kindly provided by Dr. Jochemsen and subcloned into a FLAG containing pBABEPuro vector. Retroviral infection was carried out as described previously (Deng et al., 2004) employing the packaging cell line LinXA. The infection efficiency was determined to be 30-50%. The infected cells were selected with Hygromycin (Calbiochem, 300 µg/ml for Mv1Lu or 12 µg/ml for HMEC) or Puromycin (2 ng/ml, Fluka). HMEC cells were infected at passage 9-11. For double-infections with the MDM2 deletion mutants and MDMX, cell lines already infected with MDM2 deletion mutants were infected 6 E06-09-0844 with a puromycin resistant retrovirus containing a FLAG-tagged cDNA of mdmx, and then selected with Puromycin in the presence of Hygromycin.
For the reversion experiment, MDM2 was subcloned into a HygroMarxII vector (Hannon et al., 1999) containing a loxP site in the 3'-LTR (Figure 2A ). Cells transduced with this construct were infected with a second retrovirus encoding the Cre recombinase with a Puromycin resistance marker. After selection was complete, cells were cultivated for a period of 10-14 days before subjected to the indicated experiments.
Colony formation assay
The colony formation assay was performed as described previously (Sun et al., 1998) . Briefly, 2-6 x 10 3 of Mv1Lu cells or 2-8 x 10 3 of HMEC cells were seeded into 6-well plates and treated with 5 ng/ml TGF-β or left untreated for 8-12 days with a replenishment of TGF-β every 4 days. Cells were then washed, fixed and stained with crystal violet. Each experiment was repeated at least 3 times.
Analysis of cell cycle profiles using the BrdU incorporation assay followed by FACS analysis
To determine the cell cycle profiles, 1 x 10 5 cells were seeded into a 10-cm dish and treated with 5 ng/ml TGF-β for 48 h. For the last 45 min, 20 µM BrdU was added to the cells. Cells were harvested by trypsinization, washed once in PBS and fixed in 70% ethanol for at least 2 h. Subsequently cells were incubated with 2 M HCl and 0.1% Triton X100 for 30 min at 20˚C, washed first with 0.1 M Na 2 BB 4 0 7 , pH 8.5
and then with PBS containing 1% BSA and 0.5% Triton X100, and incubated with a FITC-coupled mouseanti-BrdU antibody (Pharmingen) for 30 min. After washing with PBS, cells were incubated with 10 µg/ml 7AAD (Sigma) in PBS containing 1% BSA and 0.1% Triton X100 for 10-20 min at 20˚C, followed by another wash with PBS containing 1% BSA and 0.1% TritonX 100 before subjected to FACS analysis.
Fluorescence of the cells was detected by exciting the FITC and 7AAD spectra respectively and measuring at the appropriate emission wavelength. The data were evaluated using the FCSPress software. Each experiment was repeated at least 3 times.
Analysis of TGF-ß sensitivity in synchronized cells
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Mv1Lu cells transduced with either a control vector or mdm2 were maintained under confluence for 6 days, with replenishment of medium every 2 days. Cells were then released from contact inhibition by splitting, and seeded at 1.5 X 10 6 cells/10-cm plate in the presence or absence of TGF-β to allow re-entry into the cell cycle. The cell cycle profiles were determined in cell populations grown under confluence or those that had been released from contact inhibition for 17 or 28 hours, using a BrdU incorporation assay followed by FACS analysis as described above.
Analysis of p53 transcriptional activity
To determine the transcriptional activity of p53, luciferase reporter assays were performed using the p53
reporter construct PG14 (a kind gift from Dr. Bert Vogelstein) (el-Deiry et al., 1992) and the Dual Luciferase Assay Kit (Promega) according to manufacturer's instructions. Briefly, Mv1Lu cells stably expressing the wild type or relevant mutant MDM2 proteins were transfected with 1.9 µg of PG14 and 0.1 µg of a Renilla luciferase reporter driven by an actin promoter. The Firefly luciferase activity was determined 2 days after transfection and normalized to the Renilla luciferase activity.
Immunofluorescence
Mv1Lu cells expressing the wild type or relevant MDM2 mutant proteins were seeded at a density of 1 x 10 4 cells/well in an 8-well chamber slide (Nunc) and cultivated overnight at 37˚C. The cells were fixed with 4% paraformaldehyde in PBS at 4˚C, followed by blocking with PBS containing 3% BSA and 0.1% Tween 20
for at least 1 h at 37˚C. Subsequently, the cells were incubated for 1-2 h at 20˚C with a 1:100 dilution of the mouse-anti-HA antibody (HA11) followed by 3 washes with PBS containing 1% BSA and 0.1% Tween 20.
After that, a FITC-coupled goat-anti-mouse antibody (Santa Cruz) was diluted 1:200 and incubated with the cells for 2 h at 20˚C followed by extensive washing. The well chambers were dismounted from the slide, and the slide incubated with anti-fading solution containing DAPI (Vector Laboratories) and analyzed with a fluorescence microscope.
Immunoprecipitation
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Cell lysates were prepared in a lysis buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.25% NP40 and Complete protease inhibitors (Roche). The total protein concentration was determined by a Bradford protein assay (Bio-Rad) and 0.2 -1 mg of proteins was used for immunoprecipitation. The remaining lysate was used as a whole cell lysate control during Western Blotting.
2-10 µg of antibody was added to the lysate and incubated at 4˚C for 2 h. 10-20 µl of a 50 % slurry of Protein G-Sepharose (GE Healthcare) were added, and the reactions were incubated for an additional hour at 4˚C.
The beads were pelleted by centrifugation at 200 g, washed 4 times with lysis buffer, mixed with 50 µl of SDS sample buffer (Invitrogen), and incubated at 95˚C for 5 min. After cooling, the beads were subjected to SDS-PAGE followed by Western Blotting.
Results
MDM2 mediates TGF-β resistance by overcoming TGF-β induced G1 arrest
mdm2 has been identified in a functional cDNA library screen designed to search for genes that could bypass TGF-β induced growth arrest in a mink lung epithelial cell line Mv1Lu (Sun et al., 1998) . To confirm the ability of MDM2 to confer TGF-β resistance, Mv1Lu cells were stably transduced with mdm2 using a retroviral vector and, immediately after selection of infected cells (7-10 days post infection), were tested for TGF-β resistance. After 8 days of TGF-β treatment of sparsely seeded cells, a significantly higher number of TGF-β resistant colonies were observed in MDM2-expressing cells than in control cells ( Figure 1A ), confirming our previous observation that MDM2 confers TGF-β resistance (Sun et al., 1998) . We estimated that at least 10% of the cells in the MDM2-transduced population, while only less than 0.1% of the control cells, formed colonies in the presence of TGF-β. The high percentage of TGF-β resistant cells shortly after the transduction of mdm2 suggested that MDM2 did not confer TGF-β resistance by promoting the accumulation of secondary mutations, but rather through a direct effect.
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It has been demonstrated that TGF-β arrests cell growth in G1 phase (Laiho et al., 1990) . To determine whether MDM2 confers TGF-β resistance by abrogating TGF-β induced G1 arrest, we measured the percentage of MDM2-expressing or control cells that had progressed from G1 into S phase in the presence of TGF-β using a BrdU incorporation assay followed by FACS analysis. When treated with TGF-β, the percentage of cells incorporating BrdU (representing those in S phase) in the MDM2 expressing population was 11.8%, as compared to 3.7% in the control population, indicating that a significant portion of MDM2 expressing cells were able to exit G1 and progress into S phase in the presence of TGF-β ( Figure 1B To further substantiate the ability of MDM2 to overcome TGF-β induced G1 arrest, we analyzed cells that had been synchronized in G1 by contact inhibition and then released from G1 in the presence or absence of TGF-β. Both MDM2-expressing and control cells arrested in G1 phase when grown to confluence, suggesting that MDM2 could not overcome the G1 arrest induced by contact inhibition ( Figure 1D ). When released from contact inhibition without TGF-β, MDM2 expressing cells entered S phase faster than the control cells. 28 hours after the release, 32.4 % of MDM2-expressing cells had already proceeded from G1 into S phase, whereas there were only 11.2 % of S phase cells in the control population. This finding is consistent with a previous report that MDM2 can promote the transition of cell cycle from G1 to S-phase (Argentini et al., 2000) and overcome G1 arrest induced by multiple mechanisms (Dubs-Poterszman et al., 1995; Loughran and La Thangue, 2000) . More importantly, in the presence of TGF-β, the MDM2 cells E06-09-0844 progressed into cell cycle upon release, but the re-entry of the control cells was completely blocked.
Therefore, our results suggest that MDM2 has an intrinsic ability to enhance G1/S transition, and that this G1/S promoting activity of MDM2 allows cells to escape the negative regulation of the G1 machinery imposed by TGF-β and proliferate in the presence of TGF-β. Notably, MDM2 did not overcome the G1 arrest caused by contact inhibition, implying that TGF-β and contact inhibition induce G1 arrest through different mechanisms.
Western Blot analysis showed distinct MDM2 expression in mdm2-transduced cells, but not in control cells ( Figure 1E ). However, there is no significant decrease in the p53 protein level in MDM2-expressing cells.
This coincides with a previous finding that MDM2 overexpression alone is not always sufficient to downregulate p53 protein levels, but that MDM2 requires MDMX as a cofactor for degradation of the p53
protein (Badciong and Haas, 2002) . Indeed, co-expression of MDMX and MDM2 led to a marked decrease in the p53 protein level. This suggests that MDMX and MDM2 work in conjunction to inhibit and degrade p53.
Removal of MDM2 expression reverses TGF-β resistance in Mv1Lu cells
MDM2 inhibits the functions of p53, which is important for the maintenance of genome stability. Indeed, MDM2 overexpression has been shown to lead to centrosome hyperamplification and genome instability in certain tumors (Carroll et al., 1999) . Thus, it is conceivable that increased expression of MDM2 may promote genomic instability, resulting in mutations that in turn lead to TGF-β resistance. In an attempt to determine whether MDM2 mediates TGF-β resistance directly or through secondary genomic mutation, a retrovirus was constructed which contained loxP sites flanking the mdm2 cDNA. The Cre recombinase can recombine the two loxP sites and thus excises the DNA in between (Figure 2A ) (Hannon et al., 1999) . Upon transduction of loxP-mdm2-loxP infected cells with a second retrovirus encoding Cre, the mdm2 cDNA will be excised from the genome, and its expression will be lost after cell division (Figure 2A, B ). This allows a direct assessment of the effect of loss of MDM2 expression on TGF-β sensitivity.
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The infection of Mv1Lu cells with the loxP-mdm2-loxP retrovirus led to MDM2 overexpression ( Figure 2C) and TGF-β resistance as detected in a colony formation assay. Subsequently those MDM2 expressing cells were infected with a second retrovirus encoding Cre. After 2 weeks of cultivation, MDM2 was no longer detected by Western Blotting while those cells infected with an empty vector retained MDM2 expression ( Figure 2C ). The cells that had lost MDM2 expression upon Cre expression did not confer TGF-β resistance as detected in a colony formation assay ( Figure 2D ). In contrast, MDM2-expressing cells that were infected with a control vector clearly showed TGF-β resistance. This indicates that the TGF-β resistant phenotype is reversible upon removal of the exogenously expressed mdm2 gene. Therefore, our results demonstrated that MDM2 confers TGF-β resistance by directly interfering with the cellular machinery that mediates the growth inhibition in response to TGF-β, rather than by promoting secondary genomic mutations as has been suggested elsewhere (Blain and Massague, 2000) . The high percentage (10%) of TGF-β resistant cells in an MDM2-expressing population is also inconsistent with the statistical rate of the occurrence of random mutations. The differences between our observations and those obtained by BLAIN et al. may be resulted from the differential experimental conditions used in these studies.
The C-terminal half of the p53-binding domain of MDM2 is essential for MDM2-mediated TGF-β resistance
To identify the functional domains of MDM2 that contribute to TGF-β resistance, we performed a series of deletion analysis of MDM2 ( Figure 6 ). The first set of deletion mutants targeted the N-terminus of MDM2.
The deletion MDM2ΔN1 represented a known splice variant of HDM2 in the mouse protein, which had lost its p53-binding ability in vitro, but retained tumorigenic activity (Sigalas et al., 1996; Harris, 2005) .
MDM2ΔN2 targeted the complete p53-binding domain of MDM2. Consistent with our previous report (Sun et al., 1998) , MDM2ΔN1 conferred TGF-β resistance to the same extent as wild type MDM2 as detected by a BrdU incorporation assay followed by FACS analysis. Both wild type MDM2 and MDM2ΔN1 greatly In order to measure the effect of MDM2 on the transcriptional activity of p53, a luciferase reporter assay was conducted using PG14, a Firefly luciferase reporter for p53 containing 14 repeats of a synthetic p53-binding site (el-Deiry et al., 1992) . The PG14 reporter was transiently transfected into Mv1Lu cells stably expressing either wild type MDM2 or one of the deletion mutants of MDM2 to detect endogenous p53 activity. A Renilla luciferase construct driven by a β-actin promoter was co-transfected together with PG14 to allow normalization of the luciferase readout. MDM2 and MDM2ΔN1 led to comparable levels of downregulation of transcription from the PG14 reporter, while MDM2ΔN2 had lost its ability to inhibit the p53-dependent transcription ( Figure 3C ). This observation raises the possibility that, even though MDM2ΔN1 has been described to have lost its binding affinity to p53 in vitro (Sun et al., 1998; Bartel et al., 2004) , it may still bind to p53 in vivo, thus leading to the inhibition of p53 transcriptional activity.
We tested this hypothesis in a co-immunoprecipitation experiment with endogenous p53. Due to the lack of a suitable antibody for immunoprecipitating mink p53, we transduced HEK293T or HMEC with a retrovirus suggests that p53 does not interact with a second p53-binding site in the acidic domain of MDM2 as reported recently (Ma et al., 2006) .
The zinc coordination residues of the RING finger domain of MDM2 are indispensable for MDM2-mediated TGF-β resistance
The RING finger domain of MDM2 has multiple functions. It has been described to have an E3 ubiquitin protein ligase activity, which is important for the ubiquitination of p53 and MDM2 itself (Honda et al., 1997) . In addition, the RING finger domain can bind to nucleotides such as ATP and a specific RNA sequence involved in gene translation (Elenbaas et al., 1996; Poyurovsky et al., 2003) . Furthermore, the RING finger domain interacts with other proteins such as MDMX (Elenbaas et al., 1996; Tanimura et al., 1999) and TAFII250 (Leveillard and Wasylyk, 1997) . To examine the role of the RING finger, we deleted the entire RING finger domain from MDM2 (MDM2ΔC1) and tested for the ability of this mutant to confer TGF-β resistance. TGF-β treatment led to a 5-fold reduction in the percentage of cells progressing from G1
into S phase in the population that overexpressed MDM2ΔC1, as in the control population ( Figure 3A ). In addition, MDM2ΔC1 failed to promote colony formation in the presence of TGF-β in both Mv1Lu cells ( Figure 3A ) and HMEC cells ( Figure 3F ). These results indicate that the RING finger domain is essential for the ability of MDM2 to mediate TGF-β resistance.
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Western Blot analysis revealed that overexpression of MDM2ΔC1 led to a marked increase in the p53 protein level as compared to that of wild type MDM2 ( Figure 3D ). This observation is in accordance with a previous report demonstrating that loss of the E3 activity of MDM2 is accompanied by p53 stabilization and increased p53 levels in cells (Fang et al., 2000) .
In order to determine which RING finger-associated activity of MDM2 was required for TGF-β resistance, five point mutants of MDM2 were created within the RING finger domain. Four of these point mutants targeted the zinc coordination residues essential for the E3 activity (MDM2C436L, MDM2H455S, MDM2C459S and MDM2C473G) (Fang et al., 2000) , while the other targeted the ATP and RNA binding abilities of MDM2 (MDM2G446S) (Elenbaas et al., 1996) . After the expression of these mutants was confirmed by Western Blot ( Figure 4B ), they were tested for their ability to confer TGF-β resistance. All mutants that targeted the zinc coordination residues of the RING finger destroyed the ability of MDM2 to confer TGF-β resistance. These MDM2 mutants failed to bypass TGF-β induced cell cycle arrest ( Figure   4A ), and did not promote colony formation in TGF-β in Mv1Lu or HMEC cells ( Figure 4E ). In contrast, the G446S mutation did not interfere with the ability of MDM2 to mediate TGF-β resistance ( Figure 4A and 4E). These results clearly suggest an essential role of the zinc coordination residues within the RING finger, and imply that the E3 ubiquitin ligase activity may be required for MDM2-mediated TGF-β resistance. In contrast, the ATP and RNA binding activities of the RING finger are dispensable.
Similar to MDM2ΔC1, all the MDM2 point mutants that have lost one of the zinc coordination residues and thus the E3 activity, led to a stabilization of p53, while MDM2G446S targeting the RNA binding activity failed to do so ( Figure 4B ). This is again consistent with the previous finding that MDM2 mutants lacking the E3 activity stabilize p53 and lead to increased p53 protein levels in cells (Fang et al., 2000) . To determine the effect of the RING finger point mutations on the transcriptional activity of p53, Mv1Lu cells expressing these mutants were subjected to a luciferase reporter assay using the p53-dependent PG14
reporter. MDM2 expression reduced p53 reporter activity by 4-fold ( Figure 4C ). The MDM2G446S mutant also led to a similar level of inhibition of p53 activity. Surprisingly, the MDM2 mutants with altered zinc 15 E06-09-0844 coordination residues either partially (MDM2H455S and C473G) or completely (MDM2C436L and C459S) retained the ability to inhibit p53 activity. These results indicate that the zinc coordination residues of the RING finger of MDM2 are not essential for the inhibition of p53 transcriptional activity. Indeed, no significant reduction in the p53 protein level was observed in Mv1Lu, 293T or HMEC cells transduced with the mdm2 retrovirus ( Figure 1D , 3B, 3D, 3E, 4B and 5B), suggesting that p53 degradation might not play a major role in the inhibition of p53 activity by the retrovirally expressed MDM2. Since these zinc coordination residue mutants have an intact p53-binding domain, it is possible that binding of MDM2 to p53
is sufficient to inhibit p53 activity. Based on the observation that the zinc coordination residue mutants of MDM2 inhibited p53 activity but failed to confer TGF-β resistance, we conclude that inhibition of p53 activity by MDM2 is not sufficient to cause TGF-β resistance.
Since the zinc coordination residues may be important for the tertiary structure of the RING finger of MDM2, mutations of these residues may disrupt other functions such as protein-protein interaction, in addition to the E3 activity. Therefore, we tested whether the RING finger point mutants were still able to bind to MDMX. MDMX was co-expressed in Mv1Lu cells together with wild type MDM2 or MDM2 mutants carrying point mutations or a complete deletion (MDM2ΔC1) of the RING finger domain. Upon pulldown of MDMX, MDM2 and all the point mutants of the RING finger domain could be detected in the MDMX complex, while MDM2•C1 could not be detected ( Figure 4D ). These results indicate that the zinc coordination residue mutations of MDM2 retain the interaction with MDMX, although they can no longer confer TGF-ß resistance, suggesting that interaction between MDMX and the RING finger of MDM2 is not sufficient to lead to TGF-ß resistance. Since the nucleotide binding activity of the RING finger is also not essential, it is likely that the ability of MDM2 to mediate TGF-ß resistance relies on the E3 ubiquitin ligase activity.
Analysis of the central domains of MDM2 -requirement of the nuclear localization of MDM2 for TGF-β resistance
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The central region of MDM2 harbors the nuclear localization (NLS) and nuclear export signals (NES) as well as domains mediating interaction with key growth regulators such as p21 WAF1 (Jin et al., 2003) , Rb (Xiao et al., 1995) , p19/p14 ARF (Honda and Yasuda, 1999; Bothner et al., 2001 ) and ribosomal protein L5 (Marechal et al., 1994; Elenbaas et al., 1996) . To investigate whether the central region of MDM2 is involved in TGF-β resistance, a series of internal deletion mutants of MDM2 were constructed.
MDM2ΔNLS/p21 targeted the NLS/NES and the region responsible for enhanced turnover of the p21 WAF1 protein (amino acids 150-230). MDM2ΔNLS included a deletion of the NLS/NES only (amino acids [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] . MDM2ΔAD lacked the acidic domain (amino acids 233-285) that was essential for the ubiquitination and degradation of p53 (Argentini et al., 2001; Kawai et al., 2003) and for the binding of MDM2 to ribosomal protein L5 (Marechal et al., 1994; Elenbaas et al., 1996; Marechal et al., 1997) . MDM2Δp21/Rb contained deletion of a region downstream of the acidic domain inheriting the binding sites for p21 WAF1 , Rb and p19/p14 ARF (amino acids 271-385). These deletion mutants were transduced into Mv1Lu cells, and those cells were tested for TGF-β responsiveness.
The deletion of either the NLS/NES and the p21 degrading activity (MDM2ΔNLS/p21) or the NLS/NES alone (MDM2ΔNLS) led to abrogation of the ability of MDM2 to mediate TGF-β resistance in both BrdU incorporation assays ( Figure 5A ) and colony formation assays in both Mv1Lu and HMEC cells ( Figure 5F ).
To confirm the aberrant localization of MDM2ΔNLS, immunofluorescence analysis was performed. Deletion of the NLS/NES indeed led to abrogation of nuclear localization of MDM2 in MvLu cells. While the wild type MDM2 and the MDM2ΔAD mutant were exclusively localized in the nucleus, MDM2ΔNLS was mainly cytoplasmic ( Figure 5C ). These results suggest that MDM2-mediated TGF-β resistance requires the NLS/NES of MDM2 and its nuclear localization. Thus, the ability of MDM2 to confer TGF-β resistance may rely on a nuclear function.
In an attempt to clarify the role of MDMX in MDM2-mediated TGF-ß resistance, we expressed MDMX alone or together with MDM2 or its deletion mutants of the NLS. MDMX alone did not confer TGF-ß E06-09-0844 resistance and did not further enhance TGF-ß resistance conferred by MDM2. Interestingly, when MDMX was co-expressed with deletion mutants of the NLS of MDM2, TGF-ß resistance was observed ( Figure 5D , top). To further assess the function of MDMX, the PG14 reporter assay was employed in Mv1Lu cell lines expressing MDM2 or its NLS deletion mutants with or without MDMX. Compared to wild type MDM2, the ability of MDM2ΔNLS and MDM2Δp21/NLS to inhibit p53 activity was greatly reduced ( Figure 5D , bottom), suggesting that nuclear localization of MDM2 is crucial for p53 inhibition. MDMX alone also only modestly inhibited p53 activity. However, MDMX in combination with MDM2ΔNLS or MDM2Δp21/NLS led to p53 inhibition at a level comparable to wild type MDM2 ( Figure 5D , bottom). Taken together with our observation that co-expression of MDMX and MDM2ΔNLS or MDM2Δp21/NLS conferred TGF-β resistance, these findings suggest that a threshold of p53 inhibition must be reached in order to establish TGF-β resistance in cells. Therefore, the inhibition of p53 may be essential for MDM2-mediated TGF-ß resistance, although p53 inhibition by MDM2 alone is not sufficient to evade the growth arrest by TGF-ß ( Figure 4A, 4C, 4E) . MDM2, thus, may rely on multiple activities to confer TGF-ß resistance.
It has been reported that the acidic domain of MDM2 is important for the ubiquitination and degradation of p53 (Argentini et al., 2001; Kawai et al., 2003) . However, the acidic domain did not seem to be important for MDM2 to confer TGF-β resistance. The MDM2ΔAD mutant behaved in a similar fashion as wild type MDM2 in preventing TGF-β induced G1 arrest in Mv1Lu cells ( Figure 5A ) and in promoting colony formation in the presence of TGF-β in both Mv1Lu and HMEC cells ( Figure 5F ). This result suggests that the ubiquitination and degradation of p53 by MDM2 is not essential for TGF-β resistance. Furthermore, similar to the MDM2 mutants lacking E3 activity (the zinc coordination residue mutants), the MDM2ΔAD mutant also increased p53 protein level ( Figure 5B ) but inhibited p53 activity ( Figure 5E ) in Mv1Lu cells.
Since both the E3-defective mutants and the ΔAD mutant fail to degrade p53 but remain bound to p53, it is likely that, at least in Mv1Lu cells, binding of p53 to a MDM2 mutant that is unable to degrade p53 results in stabilization of p53 in its inactive form. Since the acidic domain also harbors the binding site for ribosomal 18 E06-09-0844 protein L5 (Elenbaas et al., 1996) , our result also indicates that binding to L5 is not required for TGF-β resistance.
The deletion of a region between residues 271 and 385, which contained binding sites to p21
WAF1
, Rb and p19/p14 ARF , did not significantly interfere with TGF-β resistance conferred by MDM2 either in the cell cycle analysis (MDM2Δp21/Rb, Figure 5A ) or in the colony formation assay ( Figure 5F ). Therefore, binding of MDM2 to p21 WAF1 , Rb and p19/p14 ARF is not required for TGF-β resistance.
The expression of these internal deletion mutants was confirmed by Western Blot analysis ( Figure 5B ). Their expression levels were either comparable to or higher than that of wild type MDM2, with the exception of MDM2Δp21/Rb. However, MDM2Δp21/Rb still conferred TGF-β resistance in spite of its lower expression level. All of the deletion mutants that failed to confer TGF-β resistance (ΔNLS/p21 and ΔNLS) showed a robust expression, indicating that their inability to cause TGF-β resistance was not due to insufficient expression levels.
Discussion
Increased expression of MDM2 is a potential mechanism for TGF-β resistance in tumors (Sun et al., 1998) .
The current study reveals a direct impact of MDM2 on cellular responses to TGF-ß, and demonstrates that the ability of MDM2 to cause TGF-β resistance relied on at least three elements of the MDM2 protein: the Cterminal half of the p53-binding domain, the nuclear localization, and the zinc coordination residues in the RING finger domain. These results were obtained in both mink lung epithelial cells and primary human mammary epithelial cells, and thus may represent general molecular mechanisms underlying the ability of MDM2 to confer TGF-β resistance.
We found that an N-terminal deletion of the p53-binding domain of MDM2 (MDM2•N1), which does not bind p53 in vitro (Sigalas et al., 1996) , was able to confer TGF-ß resistance. This mutant showed intact, E06-09-0844 although reduced, binding to p53 in vivo and inhibited p53 transcriptional activity to a level comparable to wild type MDM2. In contrast, MDM2•N2, which had completely lost p53-binding and inhibition in vivo, fails to confer TGF-ß resistance. This finding raises the possibility that inhibition of p53 transcriptional activity may be essential for TGF-ß resistance. It is unclear how MDM2•N1 binds to p53 in vivo. In accordance with the notion that only a MDM2 protein that binds and inhibits p53 is capable of mediating TGF-ß resistance, we present data suggesting that a threshold of p53 inactivation has to be surpassed in order and MDM2C459S inhibited p53 activity to the same extent as MDM2, they did not confer TGF-ß resistance.
Therefore, inhibition of p53 transcriptional activity by MDM2 on its own is not sufficient, although it might be essential, for MDM2 to confer TGF-ß resistance. Thus, MDM2 may require multiple activities to mediate TGF-ß resistance.
The inability of the zinc coordination residue mutants of MDM2 to confer TGF-β resistance suggests an essential role of the E3 ubiquitin ligase activity of MDM2. Supporting this notion, MDMX, which lacks an E3 activity, did not restore the ability of the zinc coordination residue mutants of MDM2 to mediate TGF-ß resistance (data not shown), even though it can still bind to those mutants. However, the ability of MDM2 to ubiquitinate and degrade p53 did not seem to be essential for TGF-β resistance, since an MDM2 mutant lacking the acidic domain (MDM2ΔAD) failed to degrade p53 (Argentini et al., 2001; Kawai et al., 2003) , but still led to TGF-β resistance. These observations have clearly demonstrated that TGF-β resistance can be uncoupled with the ability of MDM2 to ubiquitinate and degrade p53. It is attempting to speculate that the E3 activity of MDM2 may target an unidentified protein that mediates TGF-β induced growth arrest.
E06-09-0844
Consistent with previous reports that MDMX stimulates MDM2-mediated p53 degradation (Gu et al., 2002; Linares et al., 2003) , co-expression of MDM2 and MDMX reduces p53 protein levels ( Figure 1E ) and causes a stronger inhibition of p53 transcriptional activity as compared to MDM2 or MDMX alone ( Figure 5D ).
However, the additive effect of MDM2 and MDMX on p53 does not lead to a more pronounced TGF-ß resistance ( Figure 5D ), suggesting that MDM2 alone already has the highest possible effect on TGF-ß resistance in this system. In contrast to previous reports demonstrating that MDM2 alone downregulates p53
protein levels when transfected into cells, we consistently found that the steady state protein level of p53 was reduced only in cells co-transduced with MDM2-and MDMX-expressing retroviruses, but not in cells transduced with MDM2 or MDMX alone. This observation was made not only in mink Mv1Lu cells ( Figure   1E ), but also in human HEK293T cells ( Figure 3D ) and HMEC cells ( Figure 3E ), and thus is not mink-or cell type-specific. A difference between our and previous studies is the expression system for MDM2. In our study, expression levels of MDM2 from single-copy retroviruses are much lower in cells, in comparison with the conventional transfection methods used by previous reports. It has been reported that at low concentrations of MDM2, p53 is not degraded unless MDMX is present (Linares et al., 2003) . Therefore, in these cells, endogenous MDMX may be rate-limiting, in that it is not expressed at high enough levels to enhance the degradation of p53 by ectopically expressed MDM2 from a single-copy retrovirus.
It has been reported that in both murine and human cells, MDMX stabilizes p53 protein, possibly by competing with MDM2 for p53 binding and inhibiting the degradation of p53 by MDM2 (Jackson and Berberich, 2000; Stad et al., 2000; Gu et al., 2002) . On the other hand, efficient degradation of p53 requires both MDM2 and MDMX (Gu et al., 2002; Linares et al., 2003) . Our results agree with both of these 2 notions, in that MDMX stabilizes p53, while degradation of p53 requires both MDM2 and MDMX. We propose a possible scenario that may reconcile these observations. In this model, the MDM2-MDMX complex is more active than MDM2 alone in ubiquitinating and degrading p53. Figure 4B, 4D ). These mutations disrupt the E3 activity of MDM2 without affecting its ability to bind p53, thus effectively converting MDM2 into MDMX-like proteins, which stabilize p53 by competing with endogenous MDM2 for p53 binding. MDM2 also mediates the ubiquitination and degradation of MDMX (de Graaf et al., 2003; Pan and Chen, 2003) . Since these MDM2 mutants are defective in the E3 activity but retain the ability to bind MDMX ( Figure 4D ), they may also stabilize MDMX by competing with endogenous wild type MDM2 for MDMX binding and thus inhibiting MDMX degradation by endogenous MDM2.
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